Login to Your Account

Financings Roundup

Phase III-Ready Anticoagulant Awaits Cash from Regado IPO

By Randy Osborne
Staff Writer

Wednesday, May 1, 2013
The possibility of an initial public offering (IPO) – noted in December, when Regado Biosciences Inc. collected $51 million in a Series E financing intended to help fund Phase III trials – moved closer to reality, as the firm filed a registration statement to trade on Wall Street.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription